ProCE Banner Activity

RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML

Slideset Download
Conference Coverage
Midostaurin added to chemotherapy significantly improved survival vs placebo in patients with FLT3-mutated AML.

Released: December 11, 2015

Expiration: December 09, 2016

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen